Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices

Matthew Joseph, Manjusri Das, Suman Kanji, Jingwei Lu, Reeva Aggarwal, Debanjan Chakroborty, Chandrani Sarkar, Hongmei Yu, Hai Quan Mao, Sujit Basu, Vincent J. Pompili, Hiranmoy Das

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Despite recent advances in cardiovascular medicine, ischemic diseases remain a major cause of morbidity and mortality. Although stem cell-based therapies for the treatment of ischemic diseases show great promise, limited availability of biologically functional stem cells mired the application of stem cell-based therapies. Previously, we reported a PES-nanofiber based ex vivo stem cell expansion technology, which supports expansion of human umbilical cord blood (UCB)-derived CD133+/CD34+ progenitor cells ~225 fold. Herein, we show that using similar technology and subsequent re-expansion methods, we can achieve ~5 million-fold yields within 24 days of the initial seeding. Interestingly, stem cell phenotype was preserved during the course of the multiple expansions. The high level of the stem cell homing receptor, CXCR4 was expressed in the primary expansion cells, and was maintained throughout the course of re-expansions. In addition, re-expanded cells preserved their multi-potential differential capabilities in vitro, such as, endothelial and smooth muscle lineages. Moreover, biological functionality of the re-expanded cells was preserved and was confirmed by a murine hind limb ischemia model for revascularization. These cells could also be genetically modified for enhanced vasculogenesis. Immunohistochemical evidences support enhanced expression of angiogenic factors responsible for this enhanced neovascularization. These data further confirms that nanofiber-based ex-vivo expansion technology can generate sufficient numbers of biologically functional stem cells for potential clinical applications.

Original languageEnglish (US)
Pages (from-to)8566-8575
Number of pages10
JournalBiomaterials
Volume35
Issue number30
DOIs
StatePublished - Oct 2014

Fingerprint

Nanofibers
Stem cells
Fetal Blood
Blood Cells
Blood
Stem Cells
Cell- and Tissue-Based Therapy
Technology
CXCR4 Receptors
Angiogenesis Inducing Agents
Medicine
Muscle
Smooth Muscle
Availability
Ischemia
Extremities
Morbidity
Phenotype
Mortality

Keywords

  • Limb ischemia
  • NOD/SCID mice
  • PES-nanofiber
  • Proangiogenic growth factors
  • Re-expansion

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices. / Joseph, Matthew; Das, Manjusri; Kanji, Suman; Lu, Jingwei; Aggarwal, Reeva; Chakroborty, Debanjan; Sarkar, Chandrani; Yu, Hongmei; Mao, Hai Quan; Basu, Sujit; Pompili, Vincent J.; Das, Hiranmoy.

In: Biomaterials, Vol. 35, No. 30, 10.2014, p. 8566-8575.

Research output: Contribution to journalArticle

Joseph, M, Das, M, Kanji, S, Lu, J, Aggarwal, R, Chakroborty, D, Sarkar, C, Yu, H, Mao, HQ, Basu, S, Pompili, VJ & Das, H 2014, 'Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices', Biomaterials, vol. 35, no. 30, pp. 8566-8575. https://doi.org/10.1016/j.biomaterials.2014.06.037
Joseph, Matthew ; Das, Manjusri ; Kanji, Suman ; Lu, Jingwei ; Aggarwal, Reeva ; Chakroborty, Debanjan ; Sarkar, Chandrani ; Yu, Hongmei ; Mao, Hai Quan ; Basu, Sujit ; Pompili, Vincent J. ; Das, Hiranmoy. / Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices. In: Biomaterials. 2014 ; Vol. 35, No. 30. pp. 8566-8575.
@article{cd40e130c29a47a99ff96ca0170f6550,
title = "Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices",
abstract = "Despite recent advances in cardiovascular medicine, ischemic diseases remain a major cause of morbidity and mortality. Although stem cell-based therapies for the treatment of ischemic diseases show great promise, limited availability of biologically functional stem cells mired the application of stem cell-based therapies. Previously, we reported a PES-nanofiber based ex vivo stem cell expansion technology, which supports expansion of human umbilical cord blood (UCB)-derived CD133+/CD34+ progenitor cells ~225 fold. Herein, we show that using similar technology and subsequent re-expansion methods, we can achieve ~5 million-fold yields within 24 days of the initial seeding. Interestingly, stem cell phenotype was preserved during the course of the multiple expansions. The high level of the stem cell homing receptor, CXCR4 was expressed in the primary expansion cells, and was maintained throughout the course of re-expansions. In addition, re-expanded cells preserved their multi-potential differential capabilities in vitro, such as, endothelial and smooth muscle lineages. Moreover, biological functionality of the re-expanded cells was preserved and was confirmed by a murine hind limb ischemia model for revascularization. These cells could also be genetically modified for enhanced vasculogenesis. Immunohistochemical evidences support enhanced expression of angiogenic factors responsible for this enhanced neovascularization. These data further confirms that nanofiber-based ex-vivo expansion technology can generate sufficient numbers of biologically functional stem cells for potential clinical applications.",
keywords = "Limb ischemia, NOD/SCID mice, PES-nanofiber, Proangiogenic growth factors, Re-expansion",
author = "Matthew Joseph and Manjusri Das and Suman Kanji and Jingwei Lu and Reeva Aggarwal and Debanjan Chakroborty and Chandrani Sarkar and Hongmei Yu and Mao, {Hai Quan} and Sujit Basu and Pompili, {Vincent J.} and Hiranmoy Das",
year = "2014",
month = "10",
doi = "10.1016/j.biomaterials.2014.06.037",
language = "English (US)",
volume = "35",
pages = "8566--8575",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "30",

}

TY - JOUR

T1 - Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices

AU - Joseph, Matthew

AU - Das, Manjusri

AU - Kanji, Suman

AU - Lu, Jingwei

AU - Aggarwal, Reeva

AU - Chakroborty, Debanjan

AU - Sarkar, Chandrani

AU - Yu, Hongmei

AU - Mao, Hai Quan

AU - Basu, Sujit

AU - Pompili, Vincent J.

AU - Das, Hiranmoy

PY - 2014/10

Y1 - 2014/10

N2 - Despite recent advances in cardiovascular medicine, ischemic diseases remain a major cause of morbidity and mortality. Although stem cell-based therapies for the treatment of ischemic diseases show great promise, limited availability of biologically functional stem cells mired the application of stem cell-based therapies. Previously, we reported a PES-nanofiber based ex vivo stem cell expansion technology, which supports expansion of human umbilical cord blood (UCB)-derived CD133+/CD34+ progenitor cells ~225 fold. Herein, we show that using similar technology and subsequent re-expansion methods, we can achieve ~5 million-fold yields within 24 days of the initial seeding. Interestingly, stem cell phenotype was preserved during the course of the multiple expansions. The high level of the stem cell homing receptor, CXCR4 was expressed in the primary expansion cells, and was maintained throughout the course of re-expansions. In addition, re-expanded cells preserved their multi-potential differential capabilities in vitro, such as, endothelial and smooth muscle lineages. Moreover, biological functionality of the re-expanded cells was preserved and was confirmed by a murine hind limb ischemia model for revascularization. These cells could also be genetically modified for enhanced vasculogenesis. Immunohistochemical evidences support enhanced expression of angiogenic factors responsible for this enhanced neovascularization. These data further confirms that nanofiber-based ex-vivo expansion technology can generate sufficient numbers of biologically functional stem cells for potential clinical applications.

AB - Despite recent advances in cardiovascular medicine, ischemic diseases remain a major cause of morbidity and mortality. Although stem cell-based therapies for the treatment of ischemic diseases show great promise, limited availability of biologically functional stem cells mired the application of stem cell-based therapies. Previously, we reported a PES-nanofiber based ex vivo stem cell expansion technology, which supports expansion of human umbilical cord blood (UCB)-derived CD133+/CD34+ progenitor cells ~225 fold. Herein, we show that using similar technology and subsequent re-expansion methods, we can achieve ~5 million-fold yields within 24 days of the initial seeding. Interestingly, stem cell phenotype was preserved during the course of the multiple expansions. The high level of the stem cell homing receptor, CXCR4 was expressed in the primary expansion cells, and was maintained throughout the course of re-expansions. In addition, re-expanded cells preserved their multi-potential differential capabilities in vitro, such as, endothelial and smooth muscle lineages. Moreover, biological functionality of the re-expanded cells was preserved and was confirmed by a murine hind limb ischemia model for revascularization. These cells could also be genetically modified for enhanced vasculogenesis. Immunohistochemical evidences support enhanced expression of angiogenic factors responsible for this enhanced neovascularization. These data further confirms that nanofiber-based ex-vivo expansion technology can generate sufficient numbers of biologically functional stem cells for potential clinical applications.

KW - Limb ischemia

KW - NOD/SCID mice

KW - PES-nanofiber

KW - Proangiogenic growth factors

KW - Re-expansion

UR - http://www.scopus.com/inward/record.url?scp=84925884895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925884895&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2014.06.037

DO - 10.1016/j.biomaterials.2014.06.037

M3 - Article

C2 - 25002260

AN - SCOPUS:84925884895

VL - 35

SP - 8566

EP - 8575

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 30

ER -